Network origin in Lamine Mbow first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Subsidiary | Pharmaceuticals: Major | 20 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Lamine Mbow via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| ZURA BIO LIMITED | Biotechnology | Director/Board Member Chairman Director/Board Member Director/Board Member Chief Executive Officer Investor Relations Contact | |
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Comptroller/Controller/Auditor Comptroller/Controller/Auditor Corporate Officer/Principal Director/Board Member | |
| LONGBOARD PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member Director/Board Member Investor Relations Contact | |
| SHIRE | Pharmaceuticals: Major | Director of Finance/CFO Corporate Officer/Principal Corporate Officer/Principal | |
| NGEN INC | Medical Specialties | Director of Finance/CFO Founder | |
| MEDIVATION INC | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO | |
Astra Merck, Inc.
 Astra Merck, Inc. Pharmaceuticals: MajorHealth Technology Part of AstraZeneca PLC, Astra Merck, Inc. is a company that sells pharmaceutical products. The company is based in Orlando, FL. The company was founded by Myrtle S. Potter, Thomas A. McCourt. Astra Merck was acquired by Astra AB from Merck & Co., Inc. on July 12, 1998 for $4,400 million. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| University of California, Riverside | College/University | Undergraduate Degree Doctorate Degree | |
Renagade Therapeutics, Inc.
 Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | Biotechnology | Chief Executive Officer Director of Finance/CFO | |
| GALECTO, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| HALOZYME THERAPEUTICS, INC. | Biotechnology | Human Resources Officer Director of Finance/CFO | |
Viridos, Inc.
 Viridos, Inc. Miscellaneous Commercial ServicesCommercial Services Viridos, Inc. develops and commercializes genomic-driven solutions and products. The firm's offerings are designed for application in solutions such as human health, food, water production, and environment. The company was founded by J. Craig Venter, Hamilton O. Smith, David C. Kiernan and Juan Enriquez-Cabot in February 2005 and is headquartered in La Jolla, CA. | Miscellaneous Commercial Services | Chief Executive Officer Director/Board Member | |
| MIRATI THERAPEUTICS | Biotechnology | Human Resources Officer Director of Finance/CFO | |
| EPIRUS BIOPHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
| CAREFUSION CORPORATION | Medical Distributors | Chief Executive Officer Human Resources Officer | |
| MERCK KGAA | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| Rutgers State University of New Jersey | College/University | Undergraduate Degree Undergraduate Degree | |
| JOHNSON & JOHNSON | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Founder | |
| VIATRIS INC. | Pharmaceuticals: Major | Director/Board Member | |
Shire, Inc.
 Shire, Inc. Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Shire, Inc. develops and markets medicines for patients with rare diseases. The company is based in Lexington, KY. | Pharmaceuticals: Major | Public Communications Contact | |
| Arizona State University | College/University | Undergraduate Degree | |
The Ohio State University
 The Ohio State University Other Consumer ServicesConsumer Services Global Factory, Inc. provides collaborative manufacturing execution systems. The firm's software gather, organize & analyze demand, production & quality data from various sources and monitor key indicators & execute business processes to control, manage & optimize distributed manufacturing operations. The company was founded in 1999 and is headquartered in Santa Clara, CA. | College/University | Undergraduate Degree | |
| UCLA Anderson School of Management | College/University | Masters Business Admin | |
| ORTHOFIX MEDICAL INC. | Medical Specialties | Director/Board Member | |
| Hewlett Packard Enterprise BV | Human Resources Officer | ||
HemoShear Therapeutics, Inc.
 HemoShear Therapeutics, Inc. Medical/Nursing ServicesHealth Services HemoShear Therapeutics LLC engages in the development of human-relevant systems for applications in drug research and development. It creates human relevant systems that replicate the biology of organ systems and diseases throughout drug discovery and development. The firm's technology imposes human-derived hemodynamic forces on human primary cells to recreate human biology. The company was founded by Brian R. Wamhoff and Brett R. Blackman in 2008 and is headquartered in Charlottesville, VA. | Medical/Nursing Services | President | |
| ARRAY TECHNOLOGIES, INC. | Pharmaceuticals: Major | Director/Board Member | |
| PFIZER, INC. | Pharmaceuticals: Major | General Counsel | |
| NUVASIVE, INC. | Medical Specialties | Human Resources Officer | |
Council of Institutional Investors
 Council of Institutional Investors Miscellaneous Commercial ServicesCommercial Services Council of Institutional Investors is a non-profit association of pension funds, other employee benefit funds, endowments and foundations. The company was founded in 1985 and is headquartered in Washington DC. | Miscellaneous Commercial Services | Director/Board Member | |
| GLOBAL BLOOD THERAPEUTICS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| ANACOR PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member | |
| AIMMUNE THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Executive Officer | |
Rivus Pharmaceuticals, Inc.
 Rivus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rivus Pharmaceuticals, Inc. is a company dedicated to improving metabolic health by advancing a new class of medicines called controlled metabolic accelerators (CMAs). The company is based in Charlottesville, VA. Jayson Donald Alexander Dallas has been the CEO of the company since 2021. The company is a leader in mitochondrial biology and is developing a new class of medicines to address a primary driver of cardio-metabolic disease: obesity. Rivus' lead CMA is the investigational small molecule HU6 in development to treat obesity and associated metabolic diseases, including heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH), and type 2 diabetes. | Pharmaceuticals: Major | Chief Executive Officer | |
Flare Therapeutics, Inc.
 Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | Biotechnology | Chief Executive Officer | |
| Catenion GmbH | Corporate Officer/Principal | ||
Quintiles Transnational Corp.
 Quintiles Transnational Corp. Miscellaneous Commercial ServicesCommercial Services Quintiles Transnational Corp. provides biopharmaceutical development and commercial outsourcing services. It offers product development and integrated healthcare services, including commercial and observational solutions. The company was founded by Dennis B. Gillings and Gary Koch in September 1990 and is headquartered in Durham, NC. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Computer Sciences Corp.
 Computer Sciences Corp. Information Technology ServicesTechnology Services Computer Sciences Corp. provided information technology solutions. It operated through the global business services, global infrastructure services segments. The company was founded by Roy Nutt and Fletcher Roseberry Jones on April 16, 1959 and was headquartered in Tysons, VA. | Information Technology Services | Corporate Officer/Principal | |
DoveTail Integrated Systems, Inc.
 DoveTail Integrated Systems, Inc. BiotechnologyHealth Technology DoveTail Integrated Systems, Inc. develops platform solutions to deliver pre-engineered, pre-fabricated, pre-qualified manufacturing facilities suitable for a bio-pharmaceutical production processes including therapeutic proteins, vaccine, and fill finish configurations. The firm’s products include PlantConnex System and BioTypeKit. The company was founded by Bart van Praag and Gregg J. Pacchiana in 2010 and is headquartered in Hillsborough, NC. | Biotechnology | Chairman | |
| Csc Healthcare Systems, Inc. | Corporate Officer/Principal | ||
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Kleo Pharmaceuticals, Inc.
 Kleo Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Kleo Pharmaceuticals, Inc. is a biotechnology company, which engages in the development of biospecific compounds designed to emulate and enhance the activity of biologics. Its compounds are designed to direct the immune system to destroy cancerous or virally infected cells, and treatment of multiple myeloma and COVID-19. It offers Antibody Recruiting Molecules (ARMs),Synthetic Antibody Mimics (SyAMs), and Monoclonal Antibody Therapy Enhancers (MATEs) pipeline. The company was founded by David A. Spiegel and Roy Prieb in 2015 and is headquartered in New Haven, CT. | Miscellaneous Commercial Services | Chief Executive Officer | |
| University of Ottawa | College/University | Doctorate Degree | |
Celleron Therapeutics Ltd.
 Celleron Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue. | Pharmaceuticals: Major | Director/Board Member | |
Lakewood-Amedex, Inc.
 Lakewood-Amedex, Inc. Pharmaceuticals: MajorHealth Technology Lakewood-Amedex, Inc. engages in the development of treatment for serious infectious diseases. Its product pipeline include Nu-3 cDFU, Nu-3 Oral Mucositis, Nu-8 cUTI, and Nu-8 (Cystic Fibrosis). The company is headquartered in Sarasota, FL. | Pharmaceuticals: Major | Director/Board Member | |
| ACLARIS THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Executive Officer | |
Miramax Film NY LLC
 Miramax Film NY LLC Movies/EntertainmentConsumer Services Miramax Film NY LLC operates as a global film and television studio. It produces action, comedy, drama, documentary, family, foreign, horror, and thriller pictures. The firm also engages in dimension films label business with focus on the thriller, science fiction, and action genres; magazine publishing; and books publishing. The company was founded by Harvey Weinstein and Bob Weinstein in 1979 and is headquartered in Los Angeles, CA. | Movies/Entertainment | Chief Executive Officer | |
Roche Holding (UK) Ltd.
 Roche Holding (UK) Ltd. Pharmaceuticals: MajorHealth Technology Roche Holding (UK) Ltd. manufactures and sells drugs. It operates as a holding company for Roche Products Ltd. and Roche Diagnostics Ltd. Its pharmaceuticals include Copegus, a hepatitis C therapy, HIV inhibitor Fuzeon, and breast cancer therapy, Herceptin. The firm's consumer and professional tests include Accutrend glucose monitoring systems, CoaguChek blood coagulation tests, and the Amplicor line of DNA disease diagnostics. The company was founded in 1908 and is headquartered in Welwyn Garden City, UK. | Pharmaceuticals: Major | Corporate Officer/Principal |
Statistics
International
| United States | 44 |
| Germany | 3 |
| United Kingdom | 3 |
| Ireland | 2 |
| Netherlands | 2 |
Sectoral
| Health Technology | 33 |
| Consumer Services | 8 |
| Commercial Services | 6 |
| Distribution Services | 2 |
| Health Services | 2 |
Operational
| Director/Board Member | 110 |
| Corporate Officer/Principal | 67 |
| Independent Dir/Board Member | 42 |
| Chief Executive Officer | 27 |
| President | 19 |
Most connected contacts
| Insiders | |
|---|---|
| Garry Neil | 38 |
| Tina Nova | 29 |
| Amit Munshi | 27 |
| Jennifer Jarrett | 18 |
| Kieran Gallahue | 17 |
| Laurie Stelzer | 13 |
| Vincent Aurentz | 13 |
| Katharine Knobil | 12 |
| Steven Schoch | 11 |
| Oliver Fetzer | 11 |
| Paul Streck | 10 |
| Michael Paolucci | 10 |
| Jayson Dallas | 10 |
| Nawal Ouzren | 9 |
| Robert Lisicki | 9 |
- Stock Market
- Insiders
- Lamine Mbow
- Company connections
